Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

148
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
148
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraoperative Safety and Postoperative Complications After SMILE Pro: A Retrospective Case Series of 916 Eyes.

Journal of clinical medicine·2026
Same author

Enhancing Cataract Surgery Training Through a Secure Microscope-Integrated Live Video Supervision System.

Journal of cataract and refractive surgery·2026
Same author

Three-month outcomes of PresbyEDOF: A retrospective case study evaluating a laser-based corneal solution for presbyopia correction.

Indian journal of ophthalmology·2026
Same author

Assessment and management of dry eye disease in the UK: standardising reality-based best practice.

Eye (London, England)·2026
Same author

Could a Hazard Perception Test Be Useful in Training Cataract Surgeons?

Clinical & experimental ophthalmology·2026
Same author

Corneal Stromal Thinning and Posterior Irregularity After DMEK: Clinical Observations and Biophysical Hypotheses.

Cornea·2026

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.1K

Beyond the Label: Inconsistencies in AREDS2 Eye Supplements and a Call for Standardisation.

David Beckers1, David Lockington2, Florian Kretz1

  • 1Department of Ophthalmology, Precise Vision Ophthalmologists, Rheine, Deutschland.

Seminars in Ophthalmology
|October 18, 2025
PubMed
Summary

Most over-the-counter macular supplements in the UK do not match the evidence-based AREDS2 formula, with lower levels of key nutrients like vitamin C, vitamin E, and zinc. This discrepancy may limit their effectiveness for age-related macular degeneration (AMD).

Keywords:
AMDAreds2maculapreventionsupplements

More Related Videos

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling
05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.6K
A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

13.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.1K
Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling
05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.6K
A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

13.0K

Area of Science:

  • Ophthalmology
  • Nutritional Science
  • Public Health

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults.
  • Effective management options for nonexudative AMD are limited.
  • The Age-Related Eye Disease Study 2 (AREDS2) formulation is a key evidence-based intervention for intermediate AMD.

Purpose of the Study:

  • To systematically evaluate over-the-counter (OTC) macular supplements available in the UK.
  • To compare the composition and dosages of these supplements against the established AREDS2 formulation.
  • To identify discrepancies between marketed products and clinical evidence for AMD management.

Main Methods:

  • Collection and analysis of OTC supplements marketed for macular support in the UK.
  • Direct comparison of labeled ingredients and dosages with the AREDS2 clinical trial nutrient profile.
  • Quantitative assessment of nutrient content deviations from the AREDS2 standard.

Main Results:

  • Most analyzed supplements significantly deviated from the AREDS2 formula.
  • Average nutrient levels were substantially lower: Vitamin C (52.3% less), Vitamin E (61.2% less), Zinc (40.1% less).
  • A small minority of products fully adhered to the AREDS2 composition and dosage.

Conclusions:

  • A significant gap exists between claims made for OTC macular supplements and the AREDS2 evidence base.
  • Non-adherence to AREDS2 standards may compromise supplement efficacy for AMD.
  • Regulatory oversight is needed to ensure accurate labeling and standardized formulations for patient clarity and informed recommendations.